Hospital
Inova Health Care Services
Inova Health Care Services was paid $39.33M by Medicaid between Jan 2018 and Dec 2024, across 243 billing codes. Its largest line is 99283, emergency room visit (moderate) — 24% of everything it billed.
33Billing provider infoINOVA HEALTH CARE SERVICES
ALEXANDRIA, VA 22306
ALEXANDRIA, VA 22306
33aNPI1922139120assigned 03/08/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$39.33M
24GClaims733,996
24DCodes billed243
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#21 of 80
Median peer was paid$14.69M
This provider vs. median2.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 77,877 | $2.58M | |
| 2019 | 97,751 | $3.84M | |
| 2020 | 81,487 | $3.84M | |
| 2021 | 99,509 | $5.22M | |
| 2022 | 117,096 | $6.41M | |
| 2023 | 138,530 | $8.83M | |
| 2024incomplete | 121,746 | $8.60M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 50,381 | 43,756 | $9.25M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 33,000 | 28,554 | $6.66M |
| 96361 | Intravenous infusion, hydration; each additional hour | 14% | 15,966 | 12,883 | $5.44M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.2% | 11,357 | 10,042 | $2.43M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 3.9% | 9,247 | 3,966 | $1.53M |
| G0378 | Hospital observation service, per hour | 3.3% | 4,759 | 3,736 | $1.30M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.0% | 6,432 | 5,632 | $1.16M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.7% | 5,520 | 4,967 | $1.07M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.4% | 5,957 | 5,390 | $949K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.5% | 4,155 | 3,720 | $607K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.3% | 5,934 | 3,876 | $516K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.2% | 902 | 861 | $468K |
231 more codes
| 11045 | 1.2% | 1,140 | $465K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 2,755 | $450K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.1% | 1,406 | $425K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,575 | $383K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,674 | $355K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 513 | $355K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,281 | $346K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,892 | $305K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,537 | $248K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,566 | $246K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,688 | $236K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 488 | $220K |
| 76830 | Ultrasound, transvaginal | <1% | 2,153 | $214K |
| 29581 | <1% | 1,641 | $207K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 566 | $187K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,168 | $161K |
| 87400 | <1% | 13,266 | $146K | |
| 80053 | Comprehensive metabolic panel | <1% | 36,328 | $143K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,466 | $130K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,473 | $126K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 10,772 | $122K |
| 76642 | <1% | 1,078 | $118K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 8,615 | $114K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,529 | $105K |
| 93971 | <1% | 1,054 | $99K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 328 | $84K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 452 | $84K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 143 | $80K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 5,863 | $78K |
| 93976 | <1% | 1,050 | $77K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,110 | $72K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,855 | $71K |
| 11043 | <1% | 372 | $67K | |
| 70496 | <1% | 296 | $67K | |
| 76801 | <1% | 1,216 | $50K | |
| 76770 | <1% | 351 | $50K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 485 | $47K |
| 12001 | <1% | 186 | $47K | |
| 93970 | <1% | 336 | $42K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 241 | $41K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,546 | $36K |
| 76536 | <1% | 272 | $35K | |
| 73564 | <1% | 2,701 | $34K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,257 | $33K |
| 87420 | <1% | 2,775 | $33K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 100 | $31K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 125 | $31K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,373 | $29K |
| 97161 | <1% | 343 | $28K | |
| 83880 | <1% | 3,677 | $28K | |
| 72110 | <1% | 980 | $28K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 132 | $27K |
| 71045 | Radiologic examination, chest; single view | <1% | 10,452 | $25K |
| 77066 | Tomosynthesis, mammo | <1% | 508 | $23K |
| 73030 | <1% | 1,827 | $22K | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 83 | $22K |
| 71250 | <1% | 350 | $21K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 20,564 | $21K |
| 87040 | <1% | 3,817 | $20K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 39,705 | $20K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,097 | $19K |
| 70486 | <1% | 366 | $19K | |
| 84484 | <1% | 14,679 | $18K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 25 | $17K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 19,285 | $16K |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 799 | $16K |
| 85379 | <1% | 2,930 | $15K | |
| J3490 | Unclassified drugs | <1% | 12,490 | $15K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,827 | $14K |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,320 | $14K |
| 77080 | <1% | 244 | $14K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 6,833 | $14K |
| 77065 | Tomosynthesis, mammo | <1% | 268 | $13K |
| 12011 | <1% | 66 | $13K | |
| 73630 | <1% | 1,948 | $12K | |
| 72131 | <1% | 220 | $12K | |
| 73610 | <1% | 1,890 | $12K | |
| 73130 | <1% | 1,454 | $11K | |
| 97162 | <1% | 125 | $11K | |
| 90715 | <1% | 404 | $11K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 258 | $9K |
| 75574 | <1% | 33 | $9K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,436 | $8K |
| 74018 | <1% | 643 | $8K | |
| 70498 | <1% | 305 | $8K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 13,915 | $7K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 395 | $7K |
| 85027 | <1% | 4,234 | $7K | |
| 97165 | <1% | 116 | $6K | |
| 72100 | <1% | 232 | $6K | |
| 97597 | <1% | 87 | $6K | |
| 73110 | <1% | 1,023 | $6K | |
| 81001 | <1% | 18,838 | $6K | |
| 72141 | <1% | 44 | $6K | |
| 80061 | Lipid panel | <1% | 1,767 | $6K |
| 96376 | <1% | 6,187 | $5K | |
| S0028 | Injection, famotidine, 20 mg | <1% | 3,629 | $5K |
| 84703 | <1% | 11,780 | $5K | |
| 87081 | <1% | 10,093 | $5K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 26 | $5K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,902 | $4K |
| 97116 | <1% | 181 | $4K | |
| 83735 | <1% | 8,042 | $4K | |
| 87430 | <1% | 10,407 | $4K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 10,683 | $4K |
| 85610 | <1% | 6,387 | $4K | |
| 80143 | <1% | 1,085 | $4K | |
| 83605 | <1% | 2,484 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,810 | $3K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 590 | $3K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,490 | $3K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,079 | $3K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 187 | $3K |
| 10060 | <1% | 14 | $3K | |
| 73221 | <1% | 13 | $3K | |
| 73140 | <1% | 352 | $2K | |
| 82607 | <1% | 555 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 656 | $2K |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 5,845 | $2K |
| 83690 | <1% | 12,013 | $2K | |
| 84702 | <1% | 3,078 | $2K | |
| 36430 | <1% | 16 | $2K | |
| 80179 | <1% | 1,032 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,124 | $2K |
| 86900 | <1% | 1,641 | $2K | |
| 86140 | <1% | 1,139 | $2K | |
| 73501 | <1% | 143 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 11,620 | $2K |
| 81003 | <1% | 3,695 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,261 | $2K |
| 87077 | <1% | 4,131 | $1K | |
| 84100 | <1% | 3,305 | $1K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,767 | $1K |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 2,302 | $1K |
| J3535 | Drug administered through a metered dose inhaler | <1% | 450 | $1K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 809 | $1K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,262 | $1K |
| 82248 | <1% | 5,257 | $1K | |
| 85730 | <1% | 4,243 | $1K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,755 | $1K |
| 73590 | <1% | 139 | $1K | |
| 97750 | <1% | 29 | $981.16 | |
| 81025 | <1% | 3,923 | $979.37 | |
| 73560 | <1% | 83 | $900.34 | |
| 96367 | <1% | 315 | $890.78 | |
| 97755 | <1% | 37 | $799.36 | |
| 73080 | <1% | 200 | $764.69 | |
| 84439 | <1% | 153 | $731.82 | |
| 87070 | <1% | 2,450 | $694.92 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,118 | $665.61 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,354 | $518.43 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,438 | $512.57 |
| 71101 | <1% | 40 | $430.81 | |
| 87186 | <1% | 3,601 | $394.81 | |
| 83540 | <1% | 300 | $379.09 | |
| 73090 | <1% | 102 | $367.63 | |
| 93017 | <1% | 25 | $347.27 | |
| 83550 | <1% | 203 | $285.96 | |
| 87205 | <1% | 2,053 | $217.15 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 539 | $214.44 |
| 82550 | <1% | 585 | $208.72 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 1,350 | $204.17 |
| 82728 | <1% | 98 | $202.56 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,108 | $187.14 |
| 82570 | <1% | 58 | $183.82 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 381 | $178.64 |
| 86901 | <1% | 1,641 | $177.20 | |
| 85652 | <1% | 182 | $146.00 | |
| 85651 | <1% | 371 | $131.71 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 637 | $114.58 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,483 | $113.02 |
| 94664 | <1% | 316 | $110.72 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,271 | $94.95 |
| 86850 | <1% | 740 | $94.89 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,024 | $83.51 |
| 74022 | <1% | 14 | $82.60 | |
| 97542 | <1% | 16 | $82.12 | |
| 82746 | <1% | 79 | $69.22 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,173 | $67.49 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 281 | $56.23 |
| 82805 | <1% | 207 | $48.60 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 572 | $44.71 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 168 | $41.94 |
| 87808 | <1% | 74 | $35.13 | |
| J1815 | Injection, insulin, per 5 units | <1% | 159 | $32.37 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,046 | $31.01 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 155 | $30.68 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 656 | $29.48 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 612 | $27.87 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,655 | $26.83 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 656 | $13.20 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 27 | $12.38 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 290 | $10.96 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 285 | $9.07 |
| 82272 | <1% | 26 | $7.07 | |
| 86780 | <1% | 14 | $6.42 | |
| 99292 | <1% | 47 | $4.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 214 | $3.84 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 31 | $3.74 |
| J2471 | Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg | <1% | 71 | $0.88 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,435 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 211 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 114 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 171 | $0.00 |
| 87563 | 0% | 27 | $0.00 | |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 187 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 64 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 13 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 25 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 20 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 67 | $0.00 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 23 | $0.00 |
| 84145 | 0% | 12 | $0.00 | |
| 29125 | 0% | 12 | $0.00 | |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 21 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 695 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 130 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 16 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 177 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 12 | $0.00 |
| J8597 | Antiemetic drug, oral, not otherwise specified | 0% | 62 | $0.00 |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 0% | 65 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 97 | $0.00 |
| 88304 | 0% | 53 | $0.00 | |
| 88342 | 0% | 20 | $0.00 | |
| J7999 | Compounded drug, not otherwise classified | 0% | 29 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 68 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 13 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 20 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 28 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTALENTO, RICARDO (CORPORATE CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Inova Health Care Services | Falls Church, VA | $176.68M |
| Inova Health Care Services | Alexandria, VA | $69.02M |
| Inova Health Care Services | Leesburg, VA | $46.97M |
| Inova Health Care Services | Fairfax, VA | $33.53M |
| Inova Health Care Services | Springfield, VA | $8.88M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.